trending Market Intelligence /marketintelligence/en/news-insights/trending/w82np1h9tpm0ywjds1jv3q2 content esgSubNav
In This List

EyeGate Pharmaceuticals names director

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


EyeGate Pharmaceuticals names director

EyeGate Pharmaceuticals Inc. appointed Steven Boyd to its board.

Boyd is the chief investment officer of Armistice Capital, a New York-based equity hedge fund focused on the healthcare and consumer sectors.

Waltham, Mass.-based EyeGate is a clinical-stage specialty pharmaceutical company developing therapies to treat eye-related diseases and disorders.